Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Brie ChunJoanna PucilowskaShuChing ChangIsaac KimBenjamin NikitinYoshinobu KoguchiWilliam L RedmondBrady BernardVenkatesh RajamanickamNathan PolaskePaul A FieldsValerie ConradMark SchmidtWalter J UrbaAlison K ConlinHeather L McArthurDavid B PagePublished in: Journal for immunotherapy of cancer (2022)
Chemoimmunotherapy for metastatic TNBC with pembrolizumab and capecitabine or paclitaxel resulted in similar peripheral T-cell subset lymphodepletion without altering T-cell clonal diversity. Regression modeling methods are applicable in immune monitoring studies, such as this to identify the odds of novel T-cell clones emerging during treatment, and proliferation rates of tumor-enriched T-cell clones.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- chemotherapy induced
- advanced non small cell lung cancer
- phase ii study
- metastatic breast cancer
- metastatic colorectal cancer
- phase iii
- signaling pathway
- peripheral blood
- randomized controlled trial
- clinical trial
- open label
- rectal cancer
- epidermal growth factor receptor